Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2022; 13(2): 101-115
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.101
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.101
Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
Castalia Fernández, Department of Radiation Oncology, GenesisCare Madrid, Madrid 28043, Spain
Arturo Navarro-Martin, Department of Radiation Oncology, Institut Catalá d’Oncologia, L’Hospitalet de Llobregat, Barcelona 08908, Spain
Andrea Bobo, Department of Radiation Oncology, Hospital Ruber Internacional, Madrid 28034, Spain
Joaquín Cabrera-Rodriguez, Department of Radiation Oncology, Hospital Universitario de Badajoz, Badajoz 06080, Spain
Patricia Calvo, Department of Radiation Oncology, Hospitalario Clínico Universitario de Santiago de Compostela, Santiago de Compostela 15706, Spain
Rodolfo Chicas-Sett, Department of Radiation Oncology, ASCIRES Grupo Biomédico, Valencia 46004, Spain
Javier Luna, Department of Radiation Oncology, Hospital Fundación Jiménez Díaz, Madrid 28040, Spain
Nuria Rodríguez de Dios, Department of Radiation Oncology, Hospital del Mar, Barcelona 08003, Spain
Felipe Couñago, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid 28223, Spain
Felipe Couñago, Department of Radiation Oncology, Hospital La Luz, Madrid 28223, Spain
Felipe Couñago, Department of Medicine, School of Biomedical Sciences, Universidad Europea, Madrid 28223, Spain
Author contributions: All authors contributed to this paper with conception and design of the manuscript, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: The authors declare having no conflicts of interests related to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Castalia Fernández, MD, Staff Physician, Department of Radiation Oncology, GenesisCare Madrid, Emilio Vargas 16, Madrid 28043, Spain.
Received: February 27, 2021
Peer-review started: February 27, 2021
First decision: May 7, 2021
Revised: June 7, 2021
Accepted: January 24, 2022
Article in press: January 24, 2022
Published online: February 24, 2022
Processing time: 360 Days and 10.2 Hours
Peer-review started: February 27, 2021
First decision: May 7, 2021
Revised: June 7, 2021
Accepted: January 24, 2022
Article in press: January 24, 2022
Published online: February 24, 2022
Processing time: 360 Days and 10.2 Hours
Core Tip
Core Tip: There is strong evidence (two phase II prospective studies) to support using single-fraction stereotactic ablative body radiotherapy schemes in early stage peripheral non-small cell lung cancer. In pulmonary oligometastatic disease, there are promising outcomes and publication of one randomized prospective phase II study is pending. The association of this scheme with new systemic therapies looks promising for the future.